In addition, recent studies have indicated that CCR9 can regulate EMT-associated markers to influence the progression of cancer cells; the effects observed in other cancers include decreasing the expression of E‐cadherin, increasing the expression of N‐cadherin, and significantly upregulating the expression of MMP‐1 [33]. The gene discussed is CDH2; the disease is cancer.